Navigation Links
McLean Report on nanotechnology that may enhance medication delivery and improve MRI performance
Date:5/1/2012

Belmont, MA - Researchers at Harvard-affiliated McLean Hospital have shown a new category of "green" nanoparticles comprised of a non-toxic, protein-based nanotechnology that can non-invasively cross the blood brain barrier and is capable of transporting various types of drugs.

In an article published May 1, 2012 online in PLoS ONE, Gordana Vitaliano, MD, director of the Brain Imaging NaNoTechnology Group at the McLean Hospital Imaging Center, reported that clathrin protein, a ubiquitous protein found in human, animal, plant, bacteria and fungi cells, can been modified for use as a nanoparticle for in-vivo studies. "Clathrin has never been modified for use in vivo and offers many new and interesting possibilities for delivering drugs and medical imaging agents into the brain", said Vitaliano.

Clathrin is the body's primary delivery vehicle responsible for delivering many different types of molecules into cells. Vitaliano therefore believed that the protein's naturally potent transport capabilities might be put to practical medical use for drug delivery and medical imaging.

"This study provides a new insight into utilizing bioengineered clathrin protein as a novel nanoplatform that passes the blood brain barrier," said Vitaliano, who successfully attached different fluorescent labels, commonly used in imaging, to functionalize clathrin nanoparticles. "We were able to show that the clathrin nanoparticles could be non-invasively delivered to the central nervous system (CNS) in animals. The clathrin performed significantly."

Of major importance for future clinical applications, Vitaliano also showed that clathrin crossed and/or bypassed the blood-brain barrier without enhancers or modifications, unlike other nanoparticles. These findings open the door to exploring new and important CNS medical applications.

One important medical application for clathrin nanoparticles would be Magnetic Resonance Imaging (MRI). G
'/>"/>

Contact: Adriana Bobinchock
abobinchock@partners.org
617-855-2110
McLean Hospital
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Innophos Holdings, Inc. Reports First Quarter 2012 Results
2. 3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2011
3. Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
4. Cryo-Cell Reports Financial Results for First Quarter 2012
5. Vermillion Reports Fourth Quarter and Full Year 2011 Results
6. Soligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments
7. Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug
8. GenVec Reports Fourth Quarter and 2011 Year-End Financial Results
9. Pharma IQs Compound Management Survey Report
10. EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results
11. Phalanx Biotech Group Reports Robust Revenue Growth in 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Nashville Fertility Center announced that ... for the American Society for Reproductive Medicine (ASRM), a ... in reproductive medicine. In his new role as ... executive board and will have a voice in furthering ... actively supported ASRM since 1984 when he joined while ...
(Date:12/24/2014)... Diego, CA (PRWEB) December 23, 2014 ... where their Twitter followers can submit their #HolidayInTheLab ... themselves and their lab mates. , For those struggling ... lab mates, the Pipette.com Holiday in the Lab Contest ... Pipette.com Twitter followers to send pictures of ...
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, ... focused on gynecologic disease, announced today that investors ... , Birchview Fund LLC and several Vermillion directors ... unregistered shares of Vermillion,s common stock and warrants ... in a private placement.  Under ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich Corporation ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements ... expired on December 22, 2014, thereby completing the ... for the acquisition of the Company by Merck ... clearance satisfies another condition to closing the transaction, ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3
... ... Thompson wins $5,000 in CUNY Nobel Science Challenge. , ... New York, NY (Vocus) March 12, 2010 -- Borough of ... economics category of the 2009 CUNY Nobel Science Challenge—as well as $5,000 as an overall ...
... 11 Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection ... ... , , ... ...
... Conventional Energy seminar , ... , , ... ... EDMONTON , March 11 ...
Cached Biology Technology:BMCC Student—the Only Community College Winner—Lands Grand Prize in Nobel Science Challenge 2FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 2FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 3FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 4FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 5FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 6FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 7FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 8Alberta companies delivering new products to the Conventional Energy marketplace 2Alberta companies delivering new products to the Conventional Energy marketplace 3
(Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
(Date:12/3/2014)... 2014   Marvin Test Solutions , a ... for military, aerospace, and manufacturing organizations, today announced ... TS-900 PXI semiconductor test platform . The ... systems to customers at a fraction of the ... ATE. "Our semiconductor customers asked ...
(Date:11/21/2014)... , Nov. 20, 2014 Strict laws ... efficiency are piloting the North American and European automotive ... accidents growing, gesture recognition systems that are intuitive and ... mark in the industry. New analysis ... Gesture Recognition Market in Europe ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... Institute at Virginia Tech have discovered how abscisic ... properties for the treatment of disease, helps fight ... published in the November 2010 Journal of ... for the development of treatments for inflammatory and ...
... to have evolved a distinctly different mechanism to cause the ... of the online journal mBio . Vibrio ... cholera. While there are more than 200 different serogroups ... to cause epidemic and pandemic outbreaks of disease, using a ...
... tools developed at the University of Michigan show ... implicated in Alzheimer,s disease. A hallmark of ... aggregation of protein-like bits known as amyloid-beta peptides ... plaques and their intermediate messes can cause cell ...
Cached Biology News:Researchers discover how natural drug fights inflammation 2Researchers discover how natural drug fights inflammation 3Unraveling Alzheimer's: Simple small molecules could untangle complex disease 2
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood CD14+ monocytes, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Biology Products: